Related Experiment Video

Updated: Sep 30, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II

Enrica Capelletto1, Paolo Bironzo1, Louis Denis2

  • 1Department of Oncology, University of Turin, Italy.

Future Oncology (London, England)
|March 14, 2022
PubMed

Insights

This study investigates targeted therapies for advanced KRAS-mutant non-small-cell lung cancer (NSCLC). It compares VS-6766 alone versus VS-6766 plus defactinib in patients who have not responded to chemotherapy or immune checkpoint inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Trials

Background:

  • KRAS mutations are common in lung adenocarcinoma, particularly codon 12 mutations like p.G12C.
  • Current treatments for advanced KRAS-mutant non-small-cell lung cancer (NSCLC) are limited to chemotherapy and immune checkpoint inhibitors (CPIs).
  • There is a need for novel targeted therapies to improve outcomes for KRAS-mutant NSCLC patients.

Purpose of the Study:

  • To evaluate the efficacy and safety of VS-6766 compared to VS-6766 in combination with defactinib.
  • To assess these treatments in advanced KRAS-mutant NSCLC patients who have progressed after platinum-based chemotherapy and CPIs.
  • To explore a new treatment paradigm for a difficult-to-treat patient population.

Main Methods:

  • A randomized, phase II, open-label study (RAMP-202).
  • Patients with advanced KRAS-mutant NSCLC after failure of prior platinum-based chemotherapy and CPIs will be enrolled.
  • Treatment arms include VS-6766 monotherapy and combination therapy with VS-6766 and defactinib.

Main Results:

  • This section describes the study design and rationale; specific results are not yet available as it is a trial design description.
  • The study aims to provide data on objective response rate, progression-free survival, and safety.
  • Interim or final results will guide future treatment strategies.

Conclusions:

  • Targeted therapies like VS-6766, potentially in combination with defactinib, may offer new hope for advanced KRAS-mutant NSCLC.
  • The RAMP-202 study will provide crucial data on the efficacy and safety of this novel combination.
  • Successful outcomes could shift the treatment landscape for KRAS-mutant NSCLC.
Keywords:
KRASclinical trialnon-small-cell lung cancerprecision medicinetargeted therapy

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

8.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K